CHMP recommends adding SURPASS-CVOT results to the EU Mounjaro label

The European Medicines Agency's human medicines committee issued a positive opinion on June 25, 2026 for a type II variation to Mounjaro (tirzepatide) that updates the drug's official European product information with final results from SURPASS-CVOT, the cardiovascular outcomes trial ^[1].

According to the EMA's record of procedural steps, the variation (EMA/VR/0000310637) was accepted under category C.I.4, which covers changes to the Summary of Product Characteristics, labelling or package leaflet based on new quality, preclinical, clinical or pharmacovigilance data ^[1]. The update touches sections 4.1, 4.4, 4.8 and 5.1 of the SmPC — the sections covering therapeutic indications, special warnings and precautions, undesirable effects, and pharmacodynamic properties — and the patient package leaflet was revised to match ^[1]. Version 10.1 of the risk management plan was also submitted, and the marketing authorization holder made minor editorial and formatting changes at the same time ^[1]. The product information affected is listed as the SmPC, Annex II and the package leaflet ^[1].

What SURPASS-CVOT was

The EMA document describes SURPASS-CVOT (study code I8F-MC-GPGN) as a Phase 3, event-driven, multicentre, international, randomised, double-blind, active-comparator, parallel-group study assessing the effect of tirzepatide versus dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes ^[1]. An active-comparator design means tirzepatide was tested head to head against another approved GLP-1 medicine rather than against placebo.

The procedural document does not publish the trial's numbers — no hazard ratio, event counts, or enrollment figures appear in it — and it does not spell out the exact new wording of the indication or warnings ^[1]. The EMA points readers to the scientific discussion for the procedure and to the updated Summary of Product Characteristics for details ^[1].

One thing the record makes clear is what has not happened yet. The Commission Decision column for this variation is blank in the document, meaning the European Commission's formal legal decision had not been recorded at the time the file was published ^[1]. The EMA notes that a Commission decision is normally issued within two months of the opinion for variations falling under Article 23.1a(a) of Regulation (EU) No. 712/2012, and within one year for other procedures ^[1].

Why it matters for patients

Product information is not marketing copy. In the EU it is the legally approved description of what a medicine is authorized to treat, what its known risks are, and what the supporting evidence showed. Changing sections 4.1, 4.4, 4.8 and 5.1 means the indication itself, the precautions, the listed side effects and the clinical-trial summary all reflect the completed cardiovascular trial ^[1]. Because the package leaflet was updated in step, the information a patient in Europe reads inside the box should eventually reflect the same changes ^[1].

This is also a sequencing story. The EU opinion is dated June 25, 2026 ^[1]. The sources provided here do not include any US Food and Drug Administration action on tirzepatide and cardiovascular outcomes, so the timing, scope and wording of any US label change cannot be confirmed from this document. US labeling is set separately by the FDA, and an EU change does not automatically alter the American prescribing information.

For US readers, the practical takeaway is narrower than the headline suggests: European regulators have accepted the finished cardiovascular data into Mounjaro's official paperwork, and the details of what that data showed are in the updated SmPC and scientific discussion rather than in the procedural record cited here ^[1].

What happens next

The European Commission decision implementing the June 25, 2026 opinion had not been logged in the document reviewed, with the EMA's stated timelines allowing up to two months or up to a year depending on the procedure type ^[1]. Until that decision is issued, the updated texts are recommended rather than final.

The same EMA record shows Mounjaro's European label has been busy. On December 11, 2025 the committee accepted an extension of indication to children and adolescents aged 10 years and older with type 2 diabetes inadequately controlled with metformin, basal insulin, or both, based on final results from SURPASS-PEDS (I8F-MC-GPGV), with a Commission decision on January 22, 2026 ^[1]. On January 15, 2026 a separate variation updated section 4.6 on breast-feeding, based on a lactation study showing that after a single 5 mg dose, tirzepatide concentrations in breastmilk were undetectable to very low compared with plasma ^[1].